A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C
dc.contributor.author | Dienstag, Jules L. | en_US |
dc.contributor.author | Ghany, Marc G. | en_US |
dc.contributor.author | Morgan, Timothy R. | en_US |
dc.contributor.author | Di Bisceglie, Adrian M. | en_US |
dc.contributor.author | Bonkovsky, Herbert L. | en_US |
dc.contributor.author | Kim, Hae‐Young | en_US |
dc.contributor.author | Seeff, Leonard B. | en_US |
dc.contributor.author | Szabo, Gyongyi | en_US |
dc.contributor.author | Wright, Elizabeth C. | en_US |
dc.contributor.author | Sterling, Richard K. | en_US |
dc.contributor.author | Everson, Gregory T. | en_US |
dc.contributor.author | Lindsay, Karen L. | en_US |
dc.contributor.author | Lee, William M. | en_US |
dc.contributor.author | Lok, Anna Suk-Fong | en_US |
dc.contributor.author | Morishima, Chihiro | en_US |
dc.contributor.author | Stoddard, Anne M. | en_US |
dc.contributor.author | Everhart, James E. | en_US |
dc.date.accessioned | 2011-11-10T15:39:20Z | |
dc.date.available | 2012-10-01T18:34:50Z | en_US |
dc.date.issued | 2011-08 | en_US |
dc.identifier.citation | Dienstag, Jules L.; Ghany, Marc G.; Morgan, Timothy R.; Di Bisceglie, Adrian M.; Bonkovsky, Herbert L.; Kim, Hae‐young ; Seeff, Leonard B.; Szabo, Gyongyi; Wright, Elizabeth C.; Sterling, Richard K.; Everson, Gregory T.; Lindsay, Karen L.; Lee, William M.; Lok, Anna S.; Morishima, Chihiro; Stoddard, Anne M.; Everhart, James E. (2011). "A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C ." Hepatology 54(2): 396-405. <http://hdl.handle.net/2027.42/87145> | en_US |
dc.identifier.issn | 0270-9139 | en_US |
dc.identifier.issn | 1527-3350 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/87145 | |
dc.description.abstract | The incidence of liver disease progression among subjects with histologically advanced but compensated chronic hepatitis C is incomplete. The Hepatitis C Antiviral Long‐term Treatment against Cirrhosis Trial was a randomized study of 3.5 years of maintenance peginterferon treatment on liver disease progression among patients who had not cleared virus on peginterferon and ribavirin therapy. Patients were followed subsequently off therapy. Because maintenance peginterferon treatment did not alter liver disease progression, we analyzed treated and control patients together. Among 1,050 subjects (60% advanced fibrosis, 40% cirrhosis), we determined the rate of progression to cirrhosis over 4 years and of clinical outcomes over 8 years. Among patients with fibrosis, the incidence of cirrhosis was 9.9% per year. Six hundred seventy‐nine clinical outcomes occurred among 329 subjects. Initial clinical outcomes occurred more frequently among subjects with cirrhosis (7.5% per year) than subjects with fibrosis (3.3% per year) ( P < 0.0001). Child‐Turcotte‐Pugh (CTP) score ≥7 was the most common first outcome, followed by hepatocellular carcinoma. Following occurrence of a CTP score ≥7, the rate of subsequent events increased to 12.9% per year, including a death rate of 10% per year. Age and sex did not influence outcome rates. Baseline platelet count was a strong predictor of all clinical outcomes. During the 8 years of follow‐up, death or liver transplantation occurred among 12.2% of patients with advanced fibrosis and 31.5% of those with cirrhosis. Conclusion: Among patients with advanced hepatitis C who failed peginterferon and ribavirin therapy, the rate of liver‐related outcomes, including death and liver transplantation, is high, especially once the CTP score reaches at least 7. (H EPATOLOGY 2011) | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.title | A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI | en_US |
dc.contributor.affiliationother | Gastrointestinal Unit, Massachusetts General Hospital, and the Department of Medicine, Harvard Medical School, Boston, MA | en_US |
dc.contributor.affiliationother | Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD | en_US |
dc.contributor.affiliationother | Division of Gastroenterology, University of California–Irvine, Irvine, CA | en_US |
dc.contributor.affiliationother | Gastroenterology Service, VA Long Beach Healthcare System, Long Beach, CA | en_US |
dc.contributor.affiliationother | Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St. Louis, MO | en_US |
dc.contributor.affiliationother | Department of Medicine, University of Connecticut Health Center, Farmington, CT | en_US |
dc.contributor.affiliationother | Carolinas Medical Center, Charlotte, NC | en_US |
dc.contributor.affiliationother | New England Research Institutes, Watertown, MA | en_US |
dc.contributor.affiliationother | Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD | en_US |
dc.contributor.affiliationother | Office of the Director, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD | en_US |
dc.contributor.affiliationother | Hepatology and Liver Center, Division of Gastroenterology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA | en_US |
dc.contributor.affiliationother | Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA | en_US |
dc.contributor.affiliationother | Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado Denver, School of Medicine, Aurora, CO | en_US |
dc.contributor.affiliationother | Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA | en_US |
dc.contributor.affiliationother | Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, TX | en_US |
dc.contributor.affiliationother | Division of Virology, Department of Laboratory Medicine, University of Washington, Seattle, WA | en_US |
dc.contributor.affiliationother | Gastrointestinal Unit, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 | en_US |
dc.identifier.pmid | 21520194 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/87145/1/24370_ftp.pdf | |
dc.identifier.doi | 10.1002/hep.24370 | en_US |
dc.identifier.source | Hepatology | en_US |
dc.identifier.citedreference | Seeff LB. The history of the “natural history” of hepatitis C (1968‐2009). Liver International 2009; 29 ( Suppl. 1 ): 89 ‐ 99. | en_US |
dc.identifier.citedreference | Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow‐up study of 384 patients. Gastroenterology 1997; 112: 463 ‐ 472. | en_US |
dc.identifier.citedreference | Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, et al. Compensated cirrhosis: natural history and prognostic factors. HEPATOLOGY 1987; 7: 122 ‐ 128. | en_US |
dc.identifier.citedreference | D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986; 31: 468 ‐ 475. | en_US |
dc.identifier.citedreference | Christensen E, Schlichting P, Fauerholdt L, Juhl E, Poulsen H, Tygstrup N. Changes of laboratory variables with time in cirrhosis: prognostic and therapeutic significance. HEPATOLOGY 1985; 5: 843 ‐ 853. | en_US |
dc.identifier.citedreference | Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17‐year cohort study of 214 patients. HEPATOLOGY 2006; 43: 1303 ‐ 1310. | en_US |
dc.identifier.citedreference | Manesis EK, Papatheodoridis GV, Touloumi G, Karafoulidou A, Ketikoglou J, Kitis GE, et al. Natural course of treated and untreated chronic HCV infection: results of the nationwide Hepnet.Greece cohort study. Aliment Pharmacol Ther 2009; 29: 1121 ‐ 1130. | en_US |
dc.identifier.citedreference | Serfaty L, Aumaitre H, Chazouilleres O, Bonnand A‐M, Rosmorduc O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus‐related cirrhosis. HEPATOLOGY 1998; 27: 1435 ‐ 1440. | en_US |
dc.identifier.citedreference | Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53: 744 ‐ 749. | en_US |
dc.identifier.citedreference | Hu K‐Q, Tong MJ. The long‐term outcomes of patients with compensated hepatitis C virus‐related cirrhosis and history of parenteral exposure in the United States. HEPATOLOGY 1999; 29: 1311 ‐ 1316. | en_US |
dc.identifier.citedreference | Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al. Evolution of the HALT‐C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Controlled Clinical Trials 2004; 25: 472 ‐ 492. | en_US |
dc.identifier.citedreference | Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al.; HALT‐C Trial Investigators. Prolonged therapy of advanced chronic hepatitis C with low dose peginterferon. N Engl J Med 2008; 359: 2429 ‐ 2441. | en_US |
dc.identifier.citedreference | Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al.; Hepatitis C Antiviral Long‐term Treatment against Cirrhosis Trial Group. Peginterferon alfa‐2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015 ‐ 1023. | en_US |
dc.identifier.citedreference | Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, et al. Serum alpha‐fetoprotein levels in patients with advanced hepatitis C: results from the HALT‐C Trial. J Hepatol 2005; 43: 434 ‐ 441. | en_US |
dc.identifier.citedreference | Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, et al. Excess mortality in patients with advanced chronic hepatitis C treated with long‐term peginterferon. Hepatology 2011; 53: 1100 ‐ 1108. | en_US |
dc.identifier.citedreference | Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. HEPATOLOGY 2000; 31: 864 ‐ 871. | en_US |
dc.identifier.citedreference | Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, et al. Predicting clinical and histologic outcomes based onstandard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2010; 138: 136 ‐ 146. | en_US |
dc.identifier.citedreference | Lawson A, Hagan S, Rye K, Taguri N, Ratib S, Zaitoun AM, et al. The natural history of hepatitis C with severe hepatic fibrosis. J Hepatol 2007; 47: 37 ‐ 45. | en_US |
dc.identifier.citedreference | Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: a meta‐analysis and meta‐regression. HEPATOLOGY 2008; 48: 418 ‐ 431. | en_US |
dc.identifier.citedreference | Davis GL, Alter MJ, El‐Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)‐infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513 ‐ 521. | en_US |
dc.identifier.citedreference | Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 2010; 32: 344 ‐ 355. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.